Circassia Group PLC
LSE:CIR
Net Margin
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Peer Comparison
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| UK |
|
Circassia Group PLC
LSE:CIR
|
153.1m GBP |
Loading...
|
|
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD |
Loading...
|
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
386.2B USD |
Loading...
|
|
| US |
|
Amgen Inc
NASDAQ:AMGN
|
197.1B USD |
Loading...
|
|
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
185.2B USD |
Loading...
|
|
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
116.4B USD |
Loading...
|
|
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR |
Loading...
|
|
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
80.9B USD |
Loading...
|
|
| AU |
|
CSL Ltd
ASX:CSL
|
87.1B AUD |
Loading...
|
|
| NL |
|
argenx SE
XBRU:ARGX
|
42.1B EUR |
Loading...
|
|
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR |
Loading...
|
Market Distribution
| Min | -188 120% |
| 30th Percentile | 0% |
| Median | 0% |
| 70th Percentile | 0.1% |
| Max | 10 443.9% |
Other Profitability Ratios
Circassia Group PLC
Glance View
Circassia Group Plc is a holding company, which engages in the development and commercialization of respiratory products. The company is headquartered in Oxford, Oxfordshire and currently employs 128 full-time employees. The company went IPO on 2014-03-13. The firm operates through two segments: NIOX and COPD. The NIOX segment relates to the portfolio of products used to improve asthma diagnosis and management by measuring fractional exhaled nitric oxide (FeNO). The COPD segment relates to the Tudorza and Duaklir Pressair products marketed in the United States, where they are indicated for the maintenance treatment of patients with COPD. Its NIOX FeNO measurement and monitoring products are used by physicians around the world to help improve asthma diagnosis and management. Its FeNO diagnosis and management products helps healthcare to professionals manage their patient's asthma. Its NIOX VERO is a non-invasive, point-of-care system that provides FeNO measurements. The firm provides products and services in around 50 countries.
See Also
Net Margin is calculated by dividing the Net Income by the Revenue.
Over the last 8 months, Circassia Group PLC’s Net Margin has increased from 47.6% to 51.4%. During this period, it reached a low of 47.6% on May 30, 2022 and a high of 51.4% on Jan 31, 2023.
